Annual Report 2006 - Boehringer Ingelheim

enzymes, such as the HCV serine protease and
RNA polymerase. Such new mechanisms offer the
potential for new therapies with improved safety
and efficacy compared to current treatments of
chronic hepatitis C.
Our virology drug discovery group in Laval has
developed compounds with an alternative mode
of action for the treatment of HCV infection. In
clinical trials in infected patient volunteers, we
established the short-term-efficacy for a new anti-
viral principle and have one other compound in
clinical phase I.
Our ongoing activities in HCV continue to exploit
these antiviral targets together with other novel
approaches and are complemented by partnering
efforts. In 2006, we initiated a collaboration with
the Australian company Biota to jointly discover
and develop Biota’s novel nucleoside analogues
designed to treat HCV infections and other
diseases.
serving patients
Prescription Medicines
9